论文部分内容阅读
目的探讨亚胺培南/西司他丁联合去甲万古霉素对ICU重症获得性下呼吸道感染患者治疗效果。方法回顾性分析ICU重症获得性下呼吸道感染70例患者临床资料,其中36例采用亚胺培南/西司他丁联合去甲万古霉素治疗为观察组,其余34例采用哌拉西林/他唑巴坦联合左氧氟沙星沙星治疗为对照组,比较两组患者7d后治疗效果,并比较两组症状缓解时间、治愈时间、住院费用及不良反应。结果观察组有效率为91.67%,明显高于对照组的70.59%,两组比较差异有统计学意义(P<0.05);观察组症状缓解时间及治愈时间较对照组短,但住院费用明显高于对照组,两组比较差异有统计学意义(P<0.05);观察组不良反应发生率为22.22%,明显高于对照组的11.76%,两组比较差异有统计学意义(P<0.05)。结论亚胺培南/西司他丁联合去甲万古霉素对ICU重症获得性下呼吸道感染患者治疗显效较快、治愈时间短,但是住院费用相应增高、不良反应较多,需要临床工作中加以重视。
Objective To investigate the therapeutic effect of imipenem / cilastatin combined with norvancomycin on patients with severe acquired lower respiratory tract infection in ICU. Methods The clinical data of 70 patients with severe acquired lower respiratory tract infection in ICU were retrospectively analyzed. 36 cases were treated with imipenem / cilastatin combined with norvancomycin and the other 34 cases were treated with piperacillin / Zolbactam combined with levofloxacin sand star as control group, compared the two groups of patients after 7 days of treatment, and the two groups were compared the symptom relief time, cure time, hospitalization costs and adverse reactions. Results The effective rate of the observation group was 91.67%, which was significantly higher than that of the control group (70.59%), the difference between the two groups was statistically significant (P <0.05); the symptom relief time and the cure time in the observation group were shorter than those in the control group, The difference between the two groups was statistically significant (P <0.05). The incidence of adverse reactions in the observation group was 22.22%, significantly higher than that of the control group (11.76%), the difference was statistically significant (P <0.05) . Conclusions Imipenem / cilastatin combined with norvancomycin has a good response to intensive care unit (ICU) infection of lower respiratory tract in intensive care unit (ICU). The cure time is short, but the cost of hospitalization is higher and more adverse reactions are needed. Pay attention.